Budesonide – USA

Budesonide – USA

On Dec. 18, 2020, Federal Circuit affirmed (Rule 36 judgment) Delaware court in Uceris® litigation. This is an appeal from the United States District Court for the District of Delaware in No. 1:18-cv-01288 case.

 

Previously, Plaintiffs Bausch Health Americas, Inc., Salix Pharmaceuticals Ltd., and Cosmo Technologies Limited (collectively, “Plaintiffs”) filed complaint asserting that Defendants Actavis Laboratories FL., Inc., Actavis Pharma, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries Ltd. (collectively, “Defendants”) infringed and continue to infringe U.S. Patent Nos. 10,052,286, 10,064,878, 10,105,374, 10,143,698, 10,154,964, and 10,172,799 by filing ANDA for budesonide extended release tablets, 9 mg. On Oct 28, 2019, Delaware court issued final order & judgment finding of noninfringement in favor of Defendants.

 

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved